The Effect of a Liquid Protein Modular on Growth and Outcomes in the NICU
NCT ID: NCT01609868
Last Updated: 2018-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2012-06-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Protein Supplementation of Human Milk in Extremely Low Birth Weight Infants
NCT01991613
Post-Discharge Growth and Development of Infants Who Received Targeted Fortification in the NICU
NCT04190875
Dietary Protein in the Very-low-birth-weight Infant
NCT01208493
Neurodevelopmental and Growth Outcomes of Early, Aggressive Protein Intake in Very Low Birthweight Infants
NCT01860573
Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants
NCT02943746
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control
infants in this arm will receive the current treatment that is standard of care for these infants, powder protein modular to achieve 4 gm/kg/day
Powder protein modular
Infants will receive powder protein modular to achieve 4 grm/kg/day
experimental
this group will receive a liquid protein modular that recently became commercially avaliable, to achieve the same protein of 4 grm/kg/day as the powder comparision group
Liquid protein modular
Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Powder protein modular
Infants will receive powder protein modular to achieve 4 grm/kg/day
Liquid protein modular
Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
40 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alegent Health Bergan Mercy Medical Center
UNKNOWN
University of Nebraska
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Corrine K. Hanson, PhD
IRB Administrator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alegent Bergan Hospital
Omaha, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-16432
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.